Wealth Enhancement Advisory Services LLC Acquires 934 Shares of STAAR Surgical Company $STAA

Wealth Enhancement Advisory Services LLC boosted its holdings in shares of STAAR Surgical Company (NASDAQ:STAA) by 4.4% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 22,168 shares of the medical instruments supplier’s stock after purchasing an additional 934 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in STAAR Surgical were worth $396,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in STAA. Pinnacle Investment Management Ltd purchased a new position in STAAR Surgical during the 1st quarter valued at $1,155,000. Strs Ohio purchased a new stake in STAAR Surgical in the first quarter worth about $190,000. Caxton Associates LLP bought a new stake in STAAR Surgical during the 1st quarter valued at approximately $1,051,000. Principal Financial Group Inc. grew its holdings in shares of STAAR Surgical by 3.3% during the 1st quarter. Principal Financial Group Inc. now owns 300,204 shares of the medical instruments supplier’s stock worth $5,293,000 after acquiring an additional 9,451 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. raised its position in shares of STAAR Surgical by 40.3% in the 1st quarter. Connor Clark & Lunn Investment Management Ltd. now owns 91,800 shares of the medical instruments supplier’s stock worth $1,618,000 after acquiring an additional 26,364 shares in the last quarter. 96.70% of the stock is owned by hedge funds and other institutional investors.

STAAR Surgical Stock Performance

STAA opened at $26.83 on Tuesday. The company’s 50-day simple moving average is $26.50 and its two-hundred day simple moving average is $20.71. The stock has a market capitalization of $1.32 billion, a P/E ratio of -13.90 and a beta of 0.82. STAAR Surgical Company has a 52-week low of $13.50 and a 52-week high of $35.39.

Analysts Set New Price Targets

A number of research firms have issued reports on STAA. Piper Sandler upgraded STAAR Surgical to a “hold” rating in a report on Wednesday, June 18th. Mizuho increased their price target on shares of STAAR Surgical from $17.00 to $18.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 16th. Weiss Ratings reissued a “sell (d)” rating on shares of STAAR Surgical in a research report on Saturday, September 27th. Canaccord Genuity Group upped their price objective on shares of STAAR Surgical from $20.00 to $28.00 and gave the stock a “hold” rating in a report on Wednesday, August 6th. Finally, Stifel Nicolaus set a $28.00 target price on shares of STAAR Surgical and gave the company a “hold” rating in a research note on Thursday, August 7th. Ten equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Reduce” and a consensus price target of $20.67.

STAAR Surgical Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.